drugset / Trial / NCT02418598
AADC Gene Therapy for Parkinson's Disease
Phase 1/2
Terminated
2 enrolled
Jichi Medical University
Gene Therapy Research Institution,Co.,Ltd. · collabTakara Bio Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, efficacy of intra-putaminal infusion of AAV-hAADC-2 (adeno-associated virus encoding human aromatic L-amino acid decarboxylase) by stereotaxic surgery in patients with advanced Parkinson's disease.
Timeline
- Start
- 2015-04-14
- Primary completion
- 2018-03-31
- Completion
- 2018-03-31
Outcome
Outcome not reported
Stopped: “another clinical study for regulatory approval is planned”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AAV-hAADC-2 | Gene therapy (AAV / viral vector) | 3e+11 vg | Other |
| Subject | AAV-hAADC-2 | Gene therapy (AAV / viral vector) | 9e+11 vg | Other |